{"id":"W4283709118","doi":"10.1136/annrheumdis-2022-eular.1897","title":"POS1041 LONG-TERM EFFICACY AND SAFETY OF UPADACITINIB IN PATIENTS WITH PSORIATIC ARTHRITIS REFRACTORY TO BIOLOGIC THERAPIES: 2-YEAR RESULTS FROM THE PHASE 3 SELECT-PsA 2 STUDY","year":2022,"lang":"en","type":"article","venue":"Annals of the Rheumatic Diseases","topic":"Rheumatoid Arthritis Research and Therapies","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"ca_institutions":"Probity Medical Research","funders":"Bristol-Myers Squibb","keywords":"Medicine; Psoriatic arthritis; Adverse effect; Discontinuation; Internal medicine; Tolerability; Placebo; Psoriasis; Phases of clinical research; Clinical trial; Rheumatoid arthritis; Gastroenterology; Dermatology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001482532,0.001117524,0.00219828,0.0003760407,0.0003905447,0.00132078,0.0004288925,0.001006476,0.002457838],"category_scores_gemma":[0.00109822,0.0003480678,0.002290284,0.0004883194,0.0006300783,0.001222785,0.0003001953,0.002537769,0.0008526897],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006330328,"about_ca_system_score_gemma":0.0006524545,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0005673298,"about_ca_topic_score_gemma":0.001679709,"domain_scores_codex":[0.9995193,0.0001954956,0.00003383531,0.00007339971,0.00007170919,0.0001061383],"domain_scores_gemma":[0.9992804,0.0002014273,0.0002257273,0.00005554771,0.0000562844,0.0001806276],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.7318206,0.01169626,0.02467188,0.00196017,0.00672549,0.0004905689,0.0002190662,0.004163567,0.01842272,0.0004001188,0.007848428,0.1915812],"study_design_scores_gemma":[0.4861914,0.3447323,0.1385512,0.0003312517,0.008366616,0.001650487,0.0003413475,0.004213132,0.00557747,0.0008345197,0.009009535,0.0002007689],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9880275,0.007576591,0.0002433226,0.0003876986,0.0001217317,0.0002089544,0.001535446,0.00007823359,0.001820557],"genre_scores_gemma":[0.9914329,0.003137304,0.0002914444,0.0008349386,0.0001574021,0.000235118,0.002768639,0.00002121059,0.001120997],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002457838,"threshold_uncertainty_score":0.008222222,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02471978928592592,"score_gpt":0.3061211247237473,"score_spread":0.2814013354378213,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}